Novel Imaging Model Helps Reveal New Therapeutic Target for Pancreatic Cancer
Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. In a new study, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University, the University of Nebraska and Ionis Pharmaceuticals describe an innovative new model that not only allowed them to track drug resistance in vivo, but also revealed a new therapeutic target.